STA
GSK icon

Summit Trail Advisors’s GSK GSK Stock Holding History

Summit Trail Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.21M Buy
21,848
+15,750
+258% +$853K 0.02% 846
2025
Q4 		$302K Sell
6,098
-4,575
-43% -$213K 0.01% 1202
2025
Q3 		$465K Buy
10,673
+290
+3% +$11.3K 0.01% 1099
2025
Q2 		$403K Buy
10,383
+182
+2% +$6.95K 0.01% 806
2025
Q1 		$400K Buy
10,201
+1,367
+15% +$50K 0.01% 277
2024
Q4 		$302K Buy
8,834
+1,457
+20% +$52.5K 0.01% 290
2024
Q3 		$305K Sell
7,377
-96
-1% -$3.93K 0.01% 541
2024
Q2 		$290K Buy
7,473
+2,027
+37% +$85.3K 0.01% 503
2024
Q1 		$236K Buy
+5,446
New +$225K 0.01% 526
2018
Q4 		– Sell
-2,954
Closed -$150K – 166
2018
Q3 		$150K Sell
2,954
-1,084
-27% -$55.1K 0.03% 216
2018
Q2 		$206K Sell
4,038
-8,264
-67% -$416K 0.07% 138
2018
Q1 		$300K Buy
12,302
+3,666
+42% +$171K 0.05% 281
2017
Q4 		$406K Buy
+8,636
New +$399K 0.05% 259

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Summit Trail Advisors's GSK Position: Q1 2026 in Review

Summit Trail Advisors increased its GSK (GSK) stake by 258% in Q1 2026, buying an estimated $853K and bringing the position to 21,848 shares worth $1.21M. The position accounts for 0.02% of the portfolio, ranked #846.

Summit Trail Advisors first reported a position in GSK in Q4 2017 and has held it in 13 quarters since. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Summit Trail Advisors held 21,848 shares of GSK worth $1.21M as of Q1 2026.
  • Summit Trail Advisors bought 15,750 GSK shares in Q1 2026, an estimated $853K.
  • GSK made up 0.02% of Summit Trail Advisors's portfolio in Q1 2026, its #846 holding.
  • Summit Trail Advisors first reported a position in GSK in Q4 2017 and has held it in 13 quarters since.
  • 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Summit Trail Advisors's 13F filing for Q1 2026, filed 12 May 2026.